A novel angiogenesis-based molecular signature related to prognosis and tumor immune interactions of pancreatic cancer
Weiyu Ge,Daiyuan Shentu,Yongchao Wang,Yanling Wang,Shengbai Xue,Ming Yue,Tiebo Mao,Xiaofei Zhang,Haiyan Xu,Shumin Li,Jingyu Ma,Jiayu Yao,Jiujie Cui,Liwei Wang
DOI: https://doi.org/10.3389/fcell.2022.1001606
IF: 5.5
2022-10-07
Frontiers in Cell and Developmental Biology
Abstract:Angiogenesis, a hallmark of cancer, is related to prognosis, tumor progression, and treatment response. Nevertheless, the correlation of angiogenesis-based molecular signature with clinical outcome and immune cell infiltration has not been thoroughly studied in pancreatic cancer. In this study, multiple bioinformatics methods were combined to evaluate prognosis, immune cell infiltration, and the alterations of angiogenesis-related genes (ARGs) in PC samples, and further establish a novel angiogenesis-related gene signature. Moreover, the protein and mRNA expression levels of four angiogenesis risk genes were determined by Human Protein Atlas (HPA) database and qPCR analysis, respectively. Here, we recognized two distinct angiogenesis subtypes and two gene subtypes, and revealed the critical roles of ARGs in the tumor immune microenvironment (TIME), clinical features, and prognosis. Consequently, we established an ARGs score to predict prognosis and therapeutic response of PC patients, and validated its robust predictive ability. Additionally, the ARGs score was markedly associated with clinical outcomes, tumor mutation burden (TMB), and chemotherapeutic drug sensitivity. In brief, our findings imply that the ARGs score is a robust prognostic indicator and may contribute to the development of effective individualized therapies for PC.
cell biology,developmental biology